Section 6 of 6
References
140 sources
- Afinitor prescribing information (2026) (opens in a new tab)
- Ata et al. (2024) (opens in a new tab)
- Bernard et al. (2013) (opens in a new tab)
- Bodnar et al. (2014) (opens in a new tab)
- Boss et al. (2024) (opens in a new tab)
- Brown et al. (2018) (opens in a new tab)
- Cabometyx prescribing information (2025) (opens in a new tab)
- Cahn et al. (2023) (opens in a new tab)
- Chida et al. (2024) (opens in a new tab)
- Christ et al. (2013) (opens in a new tab)
- ClinicalTrials.gov NCT04538989 (opens in a new tab)
- ClinicalTrials.gov NCT04538989 results (opens in a new tab)
- ClinicalTrials.gov NCT05735912 (opens in a new tab)
- ClinicalTrials.gov NCT06208215 (opens in a new tab)
- ClinicalTrials.gov NCT06881992 (opens in a new tab)
- ClinicalTrials.gov NCT07262970 (opens in a new tab)
- Corbin et al. (2014) (opens in a new tab)
- Crinò et al. (2023) (opens in a new tab)
- Crippa et al. (2012) (opens in a new tab)
- Cryer et al. (2009) (opens in a new tab)
- Dai et al. (2019) (opens in a new tab)
- Dastamani et al. (2024) (opens in a new tab)
- de Carbonnières et al. (2021) (opens in a new tab)
- Demirbilek et al. (2025) (opens in a new tab)
- Dizon et al. (1999) (opens in a new tab)
- Dynkevich et al. (2013) (opens in a new tab)
- eCQI Resource Center CMS816v5 (2026) (opens in a new tab)
- El Sayed et al. (2021) (opens in a new tab)
- EMA congenital hyperinsulinism orphan designation (2016) (opens in a new tab)
- EMA insulinoma orphan designation (2024) (opens in a new tab)
- ENDO Annual Meeting (2026) (opens in a new tab)
- EU Clinical Trials Information System 2024-515447-36-00 (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2015) (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2024) (opens in a new tab)
- Friebe et al. (2024) (opens in a new tab)
- Fukuda et al. (2006) (opens in a new tab)
- Gill et al. (1997) (opens in a new tab)
- Guerrero-Pérez et al. (2026) (opens in a new tab)
- Gvoke prescribing information (2025) (opens in a new tab)
- Habibollahi et al. (2020) (opens in a new tab)
- Hackeng et al. (2023) (opens in a new tab)
- Halfdanarson et al. (2020) (opens in a new tab)
- Hendren et al. (2018) (opens in a new tab)
- Hirshberg et al. (2000) (opens in a new tab)
- Hirshberg et al. (2005) (opens in a new tab)
- Hoff and Vassilopoulou-Sellin (1998) (opens in a new tab)
- Hofland et al. (2023) (opens in a new tab)
- Hofland et al. (2024) (opens in a new tab)
- Howarth et al. (2025) (opens in a new tab)
- Howe et al. (2020) (opens in a new tab)
- Ito et al. (2015) (opens in a new tab)
- Ito et al. (2021) (opens in a new tab)
- Johnson et al. (2017) (opens in a new tab)
- Journal of Clinical Endocrinology and Metabolism insulinoma correction (2026) (opens in a new tab)
- Jürgensen et al. (2024) (opens in a new tab)
- Karamanolis et al. (2024) (opens in a new tab)
- Koch et al. (2025) (opens in a new tab)
- Komatsu et al. (2016) (opens in a new tab)
- Kulke et al. (2009) (opens in a new tab)
- Kurakawa et al. (2021) (opens in a new tab)
- Linch et al. (2021) (opens in a new tab)
- Lundholm et al. (2025) (opens in a new tab)
- Lutathera prescribing information (2024) (opens in a new tab)
- Masharani et al. (2025) (opens in a new tab)
- NCCN Neuroendocrine and Adrenal Tumors guideline (opens in a new tab)
- Niitsu et al. (2019) (opens in a new tab)
- Nockel et al. (2018) (opens in a new tab)
- Osataphan et al. (2023a) (opens in a new tab)
- Osataphan et al. (2023b) (opens in a new tab)
- Patel et al. (2018) (opens in a new tab)
- Patel et al. (2026) (opens in a new tab)
- Patti et al. (2026) (opens in a new tab)
- Pattison et al. (2025) (opens in a new tab)
- Pavel et al. (2020) (opens in a new tab)
- Pediatric Endocrine Society Annual Meeting (2026) (opens in a new tab)
- Peltola et al. (2018) (opens in a new tab)
- Peltola et al. (2021a) (opens in a new tab)
- Peltola et al. (2021b) (opens in a new tab)
- Placzkowski et al. (2009) (opens in a new tab)
- Proglycem prescribing information (2026) (opens in a new tab)
- Rezolute congenital HI breakthrough therapy release (2025) (opens in a new tab)
- Rezolute congenital HI FDA meeting release (2026) (opens in a new tab)
- Rezolute EAP patient profiles (2026) (opens in a new tab)
- Rezolute ENDO presentations release (2026) (opens in a new tab)
- Rezolute FDA review update release (2026) (opens in a new tab)
- Rezolute first quarter fiscal 2027 results release (2026) (opens in a new tab)
- Rezolute for patients page (opens in a new tab)
- Rezolute Form 10-K (2026) (opens in a new tab)
- Rezolute Form 10-Q (2026) (opens in a new tab)
- Rezolute investor event presentation (2025) (opens in a new tab)
- Rezolute January corporate presentation (2026) (opens in a new tab)
- Rezolute NICTH validation release (2024) (opens in a new tab)
- Rezolute October corporate presentation (2026) (opens in a new tab)
- Rezolute partial clinical hold release (2024) (opens in a new tab)
- Rezolute pre-BLA recommendation release (2026) (opens in a new tab)
- Rezolute prospectus supplement (2026) (opens in a new tab)
- Rezolute RIZE PES data release (2022) (opens in a new tab)
- Rezolute RIZE topline release (2022) (opens in a new tab)
- Rezolute second quarter fiscal 2024 results release (2024) (opens in a new tab)
- Rezolute September corporate presentation (2025) (opens in a new tab)
- Rezolute sunRIZE and EAP insights release (2026) (opens in a new tab)
- Rezolute sunRIZE PES presentation release (2026) (opens in a new tab)
- Rezolute sunRIZE topline release (2025) (opens in a new tab)
- Rezolute third quarter fiscal 2024 results release (2024) (opens in a new tab)
- Rezolute tumor HI breakthrough therapy release (2025) (opens in a new tab)
- Rezolute tumor HI evidence release (2023) (opens in a new tab)
- Rezolute tumor HI IND clearance release (2024) (opens in a new tab)
- Rezolute tumor HI orphan drug designation release (2024) (opens in a new tab)
- Rezolute upLIFT design alignment release (2025) (opens in a new tab)
- Rezolute upLIFT enrollment completion release (2026) (opens in a new tab)
- Rezolute upLIFT interim release (2026) (opens in a new tab)
- Rezolute upLIFT results release (2026) (opens in a new tab)
- Rizzatti et al. (2025) (opens in a new tab)
- Ryan et al. (2025) (opens in a new tab)
- Sada et al. (2020) (opens in a new tab)
- Sada et al. (2021) (opens in a new tab)
- Sandostatin LAR Depot prescribing information (2024) (opens in a new tab)
- Schubert et al. (2023) (opens in a new tab)
- Service et al. (1991) (opens in a new tab)
- Signifor prescribing information (2024) (opens in a new tab)
- Somatuline Depot prescribing information (2024) (opens in a new tab)
- Strosberg et al. (2024) (opens in a new tab)
- Strosberg et al. (2026) (opens in a new tab)
- Svensson et al. (2022) (opens in a new tab)
- Teale and Marks (1998) (opens in a new tab)
- Teale and Wark (2004) (opens in a new tab)
- Vega-Beyhart et al. (2025) (opens in a new tab)
- Veltroni et al. (2020) (opens in a new tab)
- Vezzosi et al. (2005) (opens in a new tab)
- Vezzosi et al. (2008) (opens in a new tab)
- Vu et al. (2024) (opens in a new tab)
- WHO INN Proposed List 128 (2022) (opens in a new tab)
- Wiese et al. (2023) (opens in a new tab)
- XOMA (2014) (opens in a new tab)
- XOMA (2015) (opens in a new tab)
- XOMA Form 10-K (2015) (opens in a new tab)
- XOMA Form 10-K (2016) (opens in a new tab)
- XOMA Form 10-Q (2015) (opens in a new tab)
- Yamada et al. (2020) (opens in a new tab)
- Zandee et al. (2019) (opens in a new tab)